Every hospital shelf and pharmacy counter depends on an invisible global current, the pharmaceutical supply chain. Yet this ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported topline results from its Phase 3 RECONNECT study of ZYN002 in ...

Harmony Biosciences Holdings (HRMY) is in the spotlight after announcing that its Phase 3 RECONNECT study for ZYN002 in Fragile X syndrome did not meet its main goal, citing higher than expected ...

BETHESDA, Md. — Exactly one year ago, in these pages, I implored Congress to receive classified testimony from me about State Department and CIA efforts to cover up evidence and intelligence of the so ...

Nephrotic syndrome is a clinical entity defined by heavy proteinuria, hypoalbuminemia, hyperlipidemia, and edema, stemming from various glomerular diseases. Diagnosis requires a comprehensive ...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ...

The U.S. Food and Drug Administration has granted accelerated approval to Forzinity (elamipretide) injection as the first treatment for Barth syndrome. Barth syndrome is a rare, serious, and ...

Walker Burger always loved baseball, but attending the games of his favorite team, the Atlanta Braves, used to be a physical challenge. In fact, every form of exercise was difficult. Burger, 35, has a ...

Shares of Harmony Biosciences plunged Wednesday as Fragile X syndrome continued to be "undruggable" for the biotech company.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ...

Sept 24 (Reuters) - Harmony Biosciences (HRMY.O), opens new tab said on Wednesday its experimental drug for a rare genetic disorder failed to meet the main goal in a late-stage trial, sending its ...